CV Shafiee Ardestani new

More documents

Recommendations

Info

B. Publications: [1] Shafiee Ardestani M et al 2005. Study of COX-2 inhibitors on rigidity of psudoparkinsonism induced by perphenazin in comparisons with bromocriptine in rat. 11 th congress of pharmaceutical sciences,Shiraz .Abstract book. page. 142 . [2] Shafiee Ardestani M et al 2007. Selective and Nonselective COX-2 Inhibitors Improved the Rigidity Caused by Electrical Lesion Toxicity in Substantia Nigra Neurons. The 9 th Iranian Congress of Toxicology May 15-17, 2007 Printed in Iranian Journal of Pharmaceutical Sciences, 2007, p (54) P118. [3] Shafiee Ardestani, M et al., 2007. Effects of Dexamethasone and Betamethasone as COX-2 gene expression inhibitors on rigidity in a rat model of Parkinson's disease. Indian. J. Pharmacol. 39: 235-239. [4] Shafiee Ardestani, M et al. 2007. Effects of Aspirin and Celecoxib on rigidity in a rat model of Parkinson's disease. J. Biol. Sci, 21: 3853-3858. [5] Shafiee Ardestani , M et al. 2008. Effect of compound 11g as novel selective COX-2 inhibitor on movement disorders. J Med Sci, Vol. 24 No. 3 436-441 [6] Shafiee Ardestani, M et al. 2008. COX inhibition: Catalepsy and Striatum Dopaminergic-GABAergic-Glutamatergic Neurotransmission. Nature Precedings, DOI: 10101/npre.2008.1481.1 [7] Shafiee Ardestani , M et al. 2008 .Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective COX-2 inhibition in normal and hemiparkinsonian rats. Basic. Clin. Pharmcol. Toxicol,.2008; 103 , 293–296 [8] Shafiee Ardestani , M et al. 2008. Betamethasone can significantly decrease level of striatal glutamate in animal model of Parkinson’s disease. Iranian J Pharm Res 2008 vol 7, issue 3; 299-232. [9] Shafiee Ardestani , M et al. 2008. Steroidal anti inflammatory drug betamethasone significantly alters level of striatal dopamine in a rat model of Parkinson’s disease. Nature Precedings. Doi:10.1038/npre.2008.2330.1 [10] Shafiee Ardestani M et al. 2008. Selective COX-2 but not COX-1 inhibition improves haloperidol induced catatonia by enhancing the Striatum dopaminergic neurotransmission. J Pak Med Assoc. Accepted and in press. [11] Shafiee Ardestani M et al 2008. Electrical lesion of Substantia nigra pars compacta; an alternative and convenient way to generate the animal model of Parkinson’s disease J Pharmacol Therapeutics. 2008. Accepted, in press, Now Abstract is available online [12] Shafiee Ardestani, M et al 2008. Formulation and in vitro Evaluation of Eudragit L100 piroxicam. Nature Precedings doi:10.1038/npre.2008.1544.1 [13] Shafiee Ardestani M et al 2008. Simultaneous determination of preservatives (Sodium benzoate and Potassium sorbate) in soft drinks and extracts. Under Review J Anal Chem [14] Mehdi Shafiee-Ardestani M et al. 2009. Preventive effect of ciprofloxacin on iron overload. In Press in Journal of Hematology. [15] Shafiee Ardestani M et al. 2008. Effect of Cyclooxygenase-2 inhibition on rigidity of animal model of Parkinson''s disease. Tehran University Medical Journal; Vol. 66, No. 5, Aug 309-314 [16] Shafiee Ardestani M et al 2008. ُSteroidal anti inflammatory drugs improve the movement disorders Accepted 2008. ISAC [ International Symposium of Analytical Cytology] Budapest, Hungary Abstract Book Pages: 136-138 [17] Shafiee Ardestani M et al. 2009. Significantly modified dopaminergic and glutamatergic neurotransmission in the striatum after selective COX-2 inhibition in normal and parkinsonian rats. Parkinsonism & related disorders Congress Germany 2008 accepted. [18] Shafiee Ardestani M et al. 2008. Effects of COX-2 and COX-2 gene expression inhibitors on memory-movement disorders and hippocampus-striatal cholinergic and glutamatergic neurotransmission. Journal of Volume 4, Issue 4, 1Alzheimer's and Dementia , July, Pages 768-772
[19] Shafiee Ardestani M et al. 2009. Parkinson's disease, Radiology and Molecular Imaging; an Overview on the Recent Researches. Accepted in 9 th International Congress on AD-PD disorders. Czech Republic, Prague. Accepted [20] Shafiee Ardestani M et al 2009. DEXAMETHASONE SIGNIFICANTLY MODIFIED STRIATAL DOPAMINERGIC, GLUTAMATERGIC AND GABAERGIC NEUROTRANSMISSIONS IN NORMAL AND RAT MODEL OF PARKINSON'S DISEASE. 9 th International Congress on AD-PD disorders. Czech Republic, Prague. Accepted [21] Shafiee Ardestani M et al; 2008 HPLC determination of logarithm of octanol-water partition coefficient (log-p) Iranian J Pharm Sci [Accepted] [22] Shafiee Ardestani M et al;2008. Synthesis, in vitro and in vivo evaluations of 99m Tc-DTPA-deoxyglucoseamine and 99m Tc-DTPA-(deoxyglucoseamine) 2 as novel modalities for tumor imaging. Iranian J Pharm Sci [Accepted] [23] Shafiee Ardestani M et al; 2008. Selective COX-2 but not COX-1 inhibition has controversial effects on Striatal neurotransmissions in normal and parkinsonian rats. Iranian J Pharm Sci [Accepted] [24] Shafiee Ardestani M et al 2008. Dexamethasone causes to significant changes in striatal neurotransmissions without having any improving effect on damaged neurons in normal and parkinsonian rats. [Under revision] Parkinson's Disease. [25] Shafiee Ardestani M et al 2009. A new class of MRI striatal dopaminergic receptor imaging agents. Submitted to XIX th IAGG World Congress of Gerontology and Geriatrics , Paris, France. (Accepted) [26] Shafiee Ardestani M et al 2009. Gd 3+ -DTPA-(Levodopa) 2 as a novel MRI striatal dopaminergic receptor imaging agent; Synthesis and preclinical evaluations. XXXVI International Congress of Pharmaceutical Sciences. Kyoto, Japan. (Accepted /and /selected for receiving 100000 Japanese yen as award) [27] Shafiee Ardestani M et al 2009. Dexamethasone causes significant changes in striatal neurotransmissions without having any improving effect on damaged neurons. XXXVI International Congress of Pharmaceutical Sciences. Kyoto, Japan. (Accepted) [28] Shafiee Ardestani M et al 2009. Striatal neurotransmission changes COX-2 inhibition dependent causes to improve the Parkinson's disease affiliated signs without having any improving effects on SNc damaged neurons. XXXVI International Congress of Pharmaceutical Sciences. Kyoto, Japan (Accepted) [29] Shafiee Ardestani M et al 2009. A letter on the published article in the journal of applied radiation and isotopes 64 (2006) 342–347; we should further attend on the publications. Under Challenge in Journal of APPLIED RADIATION AND ISOTOPES. [30] Shafiee Ardestani M et al. 2009. Alzheimer's disease or Parkinson's disease , which of them are more difficult for medical imaging?. Accepted for presentation in ASN-2009[American Society for Neurosciences] Chicago, United States of America, 2009 [31] Shafiee Ardestani et al. 2010. Parkinson's disease, Radiology and Molecular Imaging; an Overview on the Recent Researches. Accepted in AmericanJournal of Medical Sciences. [32]. Shafiee Ardestani et al.2010. Novel and facile methods for the synthesis of DTPA - mono-amide; a new completely revised strategy in Radiopharmaceutical Chemistry. Journal of Radioanalytical and Nuclear Chemistry. 283: 447–455. part of my PhD thesis] [33]. Shafiee Ardestani et al. 2009. Mn 2+ or Gd 3+ -Deferasirox-D-Deoxyglucosamine complexes as novel tumor Magnetic Resonance Imaging agents. Submitted to Bioconjugate Chemistry [A part of my PhD thesis]
Page 1 and 2: CURRICULUM VITA Personal Characteri
Page 3: Thesis supervisor: More than 6 Phar
Page 7 and 8: [50] Shafiee Ardestani M et al., De

CV Shafiee Ardestani new

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?